SYDNEY--(BUSINESS WIRE)--Sirtex Medical Limited (ASX:SRX) has reported revenue growth of 18 per cent to $83 million with record dose sales of 6,141 worldwide, up 23 per cent for the period ended 30 June 2012. Profit before income tax was up 54 per cent to $22 million. Net profit after tax was up 49 per cent to $17 million. EPS is 30.7 cents and net tangible assets per share were 102.8 cents.
